AIDS Advocates to Gilead: Save More Lives, Price the ‘Quad’ Reasonably

June 12, 2012
A coalition of AIDS advocates, spearheaded by AIDS Healthcare Foundation, have sent a letter today to the CEO of HIV/AIDS drug maker Gilead Sciences — John C. Martin — urging the company not to “decimate ADAP [AIDS Drug Assistance Programs]” by pricing its latest HIV/AIDS drug combination — known as the “Quad” — higher than Gilead’s Atripla, the most prescribed HIV/AIDS medication.
Yahoo! Finance